Development of a treatment algorithm for actinic keratoses: A European Consensus

European Journal of Dermatology

Volumn 18, Issue 6, 2008, Pages 651-659

  Stockfleth, Eggert ^a   Ferrandiz, Carlos ^b   Grob, Jean Jacques ^c   Leigh, Irene ^d   Pehamberger, Hubert ^e   Kerl, Helmut ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Universitatsklinik fur Dermatologie   (Austria)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Actinic keratosis; Algorithm; Field change; Squamous cell carcinoma

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; PLACEBO; RETINAL; RETINOID;

ACTINIC KERATOSIS; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CRYOTHERAPY; CURETTAGE; DERMATITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRY SKIN; ELASTOSIS; EROSION; ERYTHEMA; EUROPEAN UNION; HEALTH CARE COST; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LOW LEVEL LASER THERAPY; MEDICAL DECISION MAKING; PAIN; PARESTHESIA; PATIENT ATTITUDE; PATIENT CARE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PREVALENCE; PRURITUS; QUALITY OF LIFE; SCAR FORMATION; SKIN ABRASION; SKIN BIOPSY; SKIN BURNING SENSATION; SUNLIGHT PROTECTION; ULCER; WOUND INFECTION;

ALGORITHMS; HUMANS; KERATOSIS, ACTINIC;

EID: 57749206167     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0514     Document Type: Article

References (86)

1. Trakatelli M, Ulrich C, del Marmol V, et al. Epidemiology of non-melanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156(Suppl 3): 1-7.
2. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139: 1033-9.
3. Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-9.
4. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42(1 Pt 2): 4-7.
5. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
6. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-64.
7. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42(1 Pt 2): 4-7.
8. Quatresooz P, Piérard-Franchimont C, Paquet P, et al. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol 2008; 18(1): 6-10.
9. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42(1 Pt 2): 8-10.
10. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
11. Sterry W, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the Management of Actinic Keratoses. Source: http://www.euroderm.org/.
12. Stockfleth E, Kerl H, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16(6): 599-606.
13. Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol 2003; 139: 1216-7.
14. Heaphy Jr. MR, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000; 43(1 Pt 1): 138-50.
15. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42(1 Pt 2): 23-4.
16. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002; 10: 335-9.
17. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-502.
18. Ulrich C, Christophers E, Sterry W, et al. Skin diseases in organ transplant patients. Hautarzt 2002; 53(8): 524-33.
19. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46: 356-61.
20. Mittelbronn MA, Mullins DL, Ramos-Caro FA, et al. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677-81.
21. Czarnecki D, Meehan CJ, Bruce F, et al. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 2002; 6: 207-9.
22. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16(4): 335-9.
23. Rowert-Huber J, Patel W, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(Suppl 3): 8-12.
24. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
25. Braakhuis BJM, Tabor MP, Kummer JA, et al. A Genetic Explanation of Slaughter's Concept of Field Concerization. Cancer Res 2003; 63: 1727-30.
26. Wikonkal NM, Berg RJ, van Haselen CW, et al. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133: 599-602.
27. Tucci MG, Offidani A, Lucarini G, et al. Advances in the understanding of malignant transformation of keratinocytes: an immunohistochemical study. J Eur Acad Dermatol Venereol 1998; 10: 118-24.
28. Mortier L, Marchetti P, Delaporte E, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16 (INK4a) tumor suppressor. Cancer Lett 2002; 176: 205-14.
29. Stanimirovic A, Cupic H, Bosnjak B, et al. Expression of p53, bcl-2 and growth hormone receptor in actinic keratosis, hypertrophic type. Arch Dermatol Res 2003; 295: 102-8.
30. Bernard P, Dupuy A, Brun P, et al. Treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists: a prospective medical cost analysis. Ann Dermatol Venereol 2007; 134(6): 527-33.
31. Venna SS, Lee D, Stadecker MJ, et al. Clinical Recognition of Actinic Keratoses in a High-Risk Population. How Good Are We? Arch Dermatol 2005; 141: 507-9.
32. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg 1997; 23: 1009-19.
33. Helfand M, Gorman AK, Mahon S, et al. Actinic keratoses, final report. OHSU Evidence-based Practice Centre. http://www.cms.hhs.gov/ coverage/download/8b3-t3.pdf (last accessed 11 Jan 2007).
34. Jagdeo J, Weinstock MA, Piepkorn M, et al. Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Reliability of the histopathologic diagnosis of keratinocyte carcinomas. J Am Acad Dermatol 2007; 57(2): 279-84.
35. Reichrath J, Querings K. Histology of Epithelial Skin Tumors. In: The Nucleolus. Mark O.J. Olson, 2004; (ISBN: 0-306-47873-0).
36. Szeimies RM, Karrer S, Radakovic FS, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002; 47(2): 258-62.
37. Stern RS, Bolshakov S, Nataraj AJ, et al. p53 mutation in non-melanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 2002; 119(2): 522-6.
38. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2,5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
39. Papadavid E, Stratigos AJ, Falagas ME. Imiquimod: an immune response modifier in the treatment a precancerous skin lesions and skin cancer. Expert Opin Pharmacother 2007; 8(11): 1743-55.
40. Jorizzo JL. Current and novel treatment options for actinic keratosis. J Cutan Med Surg 2004; 8(Suppl. 3): 13-21.
41. Eberle J, Fecker LF, Forschner T, et al. Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol 2007; 156(Suppl 3): 18-24.
42. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-42.
43. Wolf Jr. JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
44. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40-5.
45. Patel W, Stockfleth E. Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol 2007; 156(Suppl 3): 53-6.
46. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998; 38(1): 77-80.
47. Gupta AK. The management of actinic keratoses in the United State with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70: 30-6.
48. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131: 176-81.
49. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther 2001; 23: 901-7.
50. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24(6): 990-1000.
51. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis 2002; 70: 4-7.
52. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.
53. Szeimies RM, Radakovic S, Calzavara-Pinton PG, et al. A pro-randomized study comparing photodynamic therapy with Melvix® to cryotherapy in actinic keratoses. J Eur Acad Dermatol Venereol 2000; 14: 235.
54. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146: 552-67.
55. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Accid Dermatol 2003; 48: 227-32.
56. Radakovic-Fijan S, Blecha-Thalhammer U, Kittler H, et al. Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study. J Am Acad Dermatol 2005; 53(5): 823-7.
57. Babilas P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur J Dermatol 2006; 16(4): 340-8.
58. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004; 30(2 Pt 2): 264-71.
59. Stockfleth E, Christophers E, Benninghoff B, et al. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004; 140: 1542.
60. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-21.
61. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% triloroacetic vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131: 176-81.
62. Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 1997; 23: 191-6.
63. Otley CC, Roenigk RK. Medium-depth chemical peeling. Semin Cutan Med Surg 1996; 15: 145-54.
64. Stone PA. The use of modified phenol for chemical face peeling. Clin Plast Surg 1998; 25: 21-44.
65. Sorg O, Tran C, Saurat JH. Cutaneous vitamins A and E in the context of ultraviolet- or chemically-induced oxidative stress. Skin Pharmacol Appl Skin Physiol 2001; 14: 363-72.
66. Odom R. Managing actinic keratoses with retinoids. J Am Acad Dermatol 1998; 39(2 Pt 3): S74-S78.
67. Campanelli A, Naldi L. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. Dermatology 2000; 205: 146-52.
68. Humphreys TR, Werth V, Dzubow L, et al. Treatment of photo-damaged skin with trichloroacetic acid and topical tretinoin. J Am Acad Dermatol 1996; 34: 638-44.
69. Ehriq T, Cockerell C, Piacquadio D, et al. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg 2006; 32: 1261-5.
70. Petrovich Z, Parker RG, Luxton G, et al. Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients. Radiother Oncol 1987; 8(1): 11-7.
71. Rowe DE, Carroll RJ, Day Jr. CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26(6): 976-90.
72. del Rosso JQ. An update on newer topical therapies for actinic keratoses: advances and applications. J Drugs Dermatol 2003; 2(1): 35-9.
73. Graham GF. Cryosurgery in the management of cutaneous malignancies. Clin Dermatol 2001; 19: 321-7.
74. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: An update and comparison. Dermatol Surg 2000; 26: 728-32.
75. Ulrich C, Hackethal M, Ulrich M, Howorka A, Forschner T, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007; 156(Suppl 3): 40-2.
76. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, Amerio P, Rønnevig J, Slade HB, Stockfleth E. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 (Suppl 2): 25-31.
77. Lubritz: RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982; 7: 631-2.
78. Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er: YAG laser. J Cutan Laser Ther 2001; 3: 63-6.
79. Moriarty M, Dunn J, Darragh A, et al. Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet 1982; 13: 364-5.
80. Schmook T, Stockfleth E. Current treatment patterns in non-melanoma skin cancer across Europe. J Dermatolog Treat 2003; 14: S3-S10.
81. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99-106.
82. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg 1987, 80: 47-54.
83. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42: 25-8.
84. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329(16): 1147-51.
85. Ulrich C, Degen A, Patel MJ, et al. Sunscreens in organ transplant patients. Nephrol Dial Transplant 2008; 23(6): 1805-8.
86. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl 2): 34-40.